Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr.

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Novavax is expected to post earnings of $0.19 ...

empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Novavax, the consensus EPS estimate for the quarter has ...

Shares of Novavax (NASDAQ:NVAX) rose on Wednesday after the company revealed U.S. FDA's request for additional clinical data ...

US biopharma Novavax (Nasdaq: NVAX) closed 20% higher on Wednesday after announcing an update on its COVID-19 vaccine. The US ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...